Literature DB >> 33971174

Extrapleural Pneumonectomy Versus Pleurectomy/Decortication for Malignant Pleural Mesothelioma.

Nicolas Zhou1, David C Rice1, Anne S Tsao2, Percy P Lee3, Cara L Haymaker4, Erin M Corsini1, Mara B Antonoff1, Wayne L Hofstetter1, Ravi Rajaram1, Jack A Roth1, Stephen G Swisher1, Ara A Vaporciyan1, Garrett L Walsh1, Reza J Mehran1, Boris Sepesi5.   

Abstract

BACKGROUND: Whether extrapleural pneumonectomy (EPP) or extended pleurectomy/decortication (P/D) is the optimal resection for malignant pleural mesothelioma remains controversial. We therefore compared perioperative outcomes and long-term survival of patients who underwent EPP versus P/D.
METHODS: Patients with the diagnosis of malignant pleural mesothelioma who underwent either EPP or P/D from 2000 to 2019 were identified from our departmental database. Propensity score matching was performed to minimize potential confounders for EPP or P/D. Survival analysis was performed by the Kaplan-Meier method and Cox multivariable analysis.
RESULTS: Of 282 patients, 187 (66%) underwent EPP and 95 (34%) P/D. Even with propensity score matching, perioperative mortality was significantly higher for EPP than for P/D (11% vs 0%; P = .031); when adjusted for perioperative mortality, median overall survival between EPP and P/D was 15 versus 22 months, respectively (P = .276). Cox multivariable analysis for the matched cohort identified epithelioid histology (hazard ratio [HR], 0.56; P = .029), macroscopic complete resection (HR, 0.41; P = .004), adjuvant radiation therapy (HR, 0.57; P = .019), and more recent operative years (HR, 0.93; P = .011)-but not P/D-to be associated with better survival. Asbestos exposure (HR, 2.35; P = .003) and pathologic nodal disease (HR, 1.61; P = .048) were associated with worse survival.
CONCLUSIONS: In a multimodality treatment setting, P/D and EPP had comparable long-term oncologic outcomes, although P/D had much lower perioperative mortality. The goal of surgical cytoreduction should be macroscopic complete resection achieved by the safest operation a patient can tolerate.
Copyright © 2022 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33971174     DOI: 10.1016/j.athoracsur.2021.04.078

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

Review 1.  New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.

Authors:  Anne S Tsao; Harvey I Pass; Andreas Rimner; Aaron S Mansfield
Journal:  J Clin Oncol       Date:  2022-01-05       Impact factor: 44.544

2.  Meta-analysis of survival after extrapleural pneumonectomy (EPP) versus pleurectomy/decortication (P/D) for malignant pleural mesothelioma in the context of macroscopic complete resection (MCR).

Authors:  Dimitrios E Magouliotis; Prokopis-Andreas Zotos; Arian Arjomandi Rad; Despoina Koukousaki; Vasiliki Vasilaki; Ioustini Portesi; Kyriakos Spiliopoulos; Thanos Athanasiou
Journal:  Updates Surg       Date:  2022-09-03

3.  Single-Center 20-Year Experience in Surgical Treatment of Malignant Pleural Mesothelioma.

Authors:  Giuseppe Mangiameli; Edoardo Bottoni; Umberto Cariboni; Giorgio Maria Ferraroli; Emanuela Morenghi; Veronica Maria Giudici; Emanuele Voulaz; Marco Alloisio; Alberto Testori
Journal:  J Clin Med       Date:  2022-08-03       Impact factor: 4.964

Review 4.  Systematic Review and Meta-Analysis of Pleurectomy/Decortication versus Extrapleural Pneumonectomy in the Treatment of Malignant Pleural Mesothelioma.

Authors:  Federica Danuzzo; Sebastiano Maiorca; Gianluca Bonitta; Mario Nosotti
Journal:  J Clin Med       Date:  2022-09-22       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.